Results 11 to 20 of about 166,627 (157)

Immunology and efficacy of MF59-adjuvanted vaccines

Human Vaccines & Immunotherapeutics, 2018
Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries.
Eun-Ju Ko, Sang-Moo Kang
doaj   +2 more sources

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. [PDF]

PLoS ONE, 2017
MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an ...
Rossella Cioncada, Marcella Maddaluno, Hoa Thi My Vo, Matthew Woodruff, Simona Tavarini, Chiara Sammicheli, Marco Tortoli, Alfredo Pezzicoli, Ennio De Gregorio, Michael C Carroll, Ugo D'Oro, Diego Piccioli   +11 more
doaj   +2 more sources

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. [PDF]

PLoS ONE, 2014
In an open label clinical study (2007), MF59-adjuvanted hemagglutinin (HA) vaccine from H5N1-A/Vietnam/1194/2004 (clade 1) was administered to subjects previously vaccinated (primed) with clade 0 H5N3 (A/duck/Singapore/97) vaccine at least 6 years ...
Surender Khurana, Elizabeth M Coyle, Milena Dimitrova, Flora Castellino, Karl Nicholson, Giuseppe Del Giudice, Hana Golding   +6 more
doaj   +6 more sources

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. [PDF]

PLoS ONE, 2012
Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA),
Rachel P J Lai, Michael S Seaman, Paul Tonks, Frank Wegmann, David J Seilly, Simon D W Frost, Celia C LaBranche, David C Montefiori, Antu K Dey, Indresh K Srivastava, Quentin Sattentau, Susan W Barnett, Jonathan L Heeney   +12 more
doaj   +3 more sources

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

Vaccines
The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these ...
Kangwei Xu, Jing Li, Xu Lu, Xiaoqin Ge, Kaiqin Wang, Jiahao Wang, Zhizhong Qiao, Yaru Quan, Changgui Li   +8 more
doaj   +2 more sources

A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis [PDF]

Iranian Journal of Basic Medical Sciences, 2016
Objective(s): In this study, for the first time, MF59 adjuvant was used to develop a cholesteryl ester transfer protein (CETP) vaccine. The efficacy of the vaccine was compared with the efficacy of CETP vaccine formulated with Alum/CpG, the formulation ...
Tamara Aghebati, Amir Hooshang Mohammadpour, Mohammad Afshar, Mahmoud Reza Jaafari, Khalil Abnous, Saeed Nazemi, Sobhan Issazadeh, Saeed Hashemzadeh, Mohammad Zare, Ali Badiee   +9 more
doaj   +3 more sources

Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine [PDF]

Journal of Advanced Biomedical Sciences, 2020
Background & Objective: The influenza virus causes hundreds of deaths in the world. Despite the availability of some authorized vaccines for all age groups and its approved beneficial effects, the influenza is still a major problem for public health ...
Alireza Loghmani, Nowruz Delirezh, Afagh Moattari   +2 more
doaj   +1 more source

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.

PLoS ONE, 2017
Intranasal vaccination is more potent than parenteral injection for the prevention of influenza. However, because the poor efficiency of antigen uptake across the nasal mucosa is a key issue, immunostimulatory adjuvants are essential for intranasal ...
Shu-Ting Ren, Xue-Mei Zhang, Peng-Fei Sun, Li-Juan Sun, Xue Guo, Tian Tian, Jian Zhang, Qi-Yuan Guo, Xue Li, Li-Jun Guo, Jin Che, Bing Wang, Hui Zhang   +12 more
doaj   +2 more sources

Formulation of hepatitis B vaccine in MF59 adjuvant and comparison of its immunization with Iran\'s commercial hepatitis B vaccine

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2018
Introduction: Hepatitis is a systemic diseasethat causes liver inflammation. The prevention of this infection is a vaccination. The commonly used vaccine to fight this disease is to use the vaccine formulated with Alum. This vaccine cannot provide immune
Reyhaneh Mirzaei, Fahimeh Nemati mansour, mehdi mahdavi   +2 more
doaj   +1 more source

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders

Human Vaccines & Immunotherapeutics, 2019
Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose.
Christine Robinson, Carly Baehr, Shirdi E. Schmiel, Claudia Accetturo, Daniel L. Mueller, Marco Pravetoni   +5 more
doaj   +2 more sources